Latest Advansource Biomaterials Corpora (ASNB) Hea
Post# of 20
Posted On: 03/08/2014 11:07:52 PM
Latest Advansource Biomaterials Corpora (ASNB) Headlines
Suburban Minerals Publishes New Website and Social Media Pages
Marketwire - Thu Feb 13, 7:15AM CST
Suburban Minerals Corp. (OTC Pink: SUBB) announced today the publishing of a new website, a Facebook page and a Twitter page as well.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AdvanSource Biomaterials Completes $100,000 Short-Term Financing with Shareholders and Management
Business Wire - Tue Aug 27, 11:04AM CDT
AdvanSource Biomaterials Corporation (OTC Markets OTCQB: ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the closing of a short-term debt financing transaction on August 22, 2013. The Company entered into Promissory Notes in the aggregate principal amount of $100,000 (the "Notes") with three long-standing shareholders and the Company's chief executive officer and chief financial officer (the "Investors"). The Notes have a six-month term and bear interest at the rate of 1.75% per month. In lieu of cash payment of interest, the Investors chose to receive Warrants exercisable into an aggregate 435,000 shares of the Company's common stock. The Warrants have a one-year term and are exercisable at a 150% premium over the closing price of the Company's common stock as of August 21, 2013, or $0.075 per share. The Notes are secured by accounts receivable from undisclosed customers. Other than legal fees of approximately $5,000, the Company paid no other transaction costs.
Suburban Minerals Publishes New Website and Social Media Pages
Marketwire - Thu Feb 13, 7:15AM CST
Suburban Minerals Corp. (OTC Pink: SUBB) announced today the publishing of a new website, a Facebook page and a Twitter page as well.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AdvanSource Biomaterials Completes $100,000 Short-Term Financing with Shareholders and Management
Business Wire - Tue Aug 27, 11:04AM CDT
AdvanSource Biomaterials Corporation (OTC Markets OTCQB: ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the closing of a short-term debt financing transaction on August 22, 2013. The Company entered into Promissory Notes in the aggregate principal amount of $100,000 (the "Notes") with three long-standing shareholders and the Company's chief executive officer and chief financial officer (the "Investors"). The Notes have a six-month term and bear interest at the rate of 1.75% per month. In lieu of cash payment of interest, the Investors chose to receive Warrants exercisable into an aggregate 435,000 shares of the Company's common stock. The Warrants have a one-year term and are exercisable at a 150% premium over the closing price of the Company's common stock as of August 21, 2013, or $0.075 per share. The Notes are secured by accounts receivable from undisclosed customers. Other than legal fees of approximately $5,000, the Company paid no other transaction costs.
(0)
(0)